Immunovant Inc (IMVT NASDAQ) stock market data APIs
$40.3696
-2.22(-5.5%)
as of July 17, 2026
Try our APIs with
free plan!
Immunovant Inc Financial Data Overview
Price chart is built with
Anychart
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Prev. Close
40.3696
Open
38.1465
High
40.7327
Low
37.8617
52 wk Range
14.32-41.23
Market Cap
8 266 M
Shares Outstanding
205 M
EPS
-0.67
Beta
0.766
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunovant Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunovant Inc data using free add-ons & libraries
Get Immunovant Inc Fundamental Data
Immunovant Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -532 492 992
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-20
- EPS/Forecast: -0.63
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunovant Inc News
New
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Immunovant, Inc. (IMVT). Shares have added about 3.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue lea...
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
The growth of the chronic inflammatory demyelinating polyneuropathy market is expected to be primarily driven by an expanding diagnosed patient population, improved disease awareness and diagnostic ra...
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Shares of Immunovant IMVT have risen 12.4% over the past month against the industry's 1.5% decline, reflecting growing investor confidence in the company's long-term prospects. The rally has been fue...
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Clinical trial update puts IMVT-1402 in focus Recent commentary around high respons...
Get Immunovant Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
